Search results
Results from the WOW.Com Content Network
Olivia Munn is sharing more details about her cancer journey, including how she’s doing now.Among many things, the 43-year-old revealed that she’s now in medically-induced menopause as part of ...
Treatment for breast cancer triggered painful vaginal symptoms, but I was too embarrassed to talk to my doctor about it. Here's how I improved my sex life. Breast Cancer Threw Me Into Menopause at ...
Olivia Munn is in medically induced menopause as a result of treatment to keep her breast cancer from recurring, the actress told People in an exclusive new interview. Munn, who last month ...
Observational studies of systemic HRT after breast cancer are generally reassuring. If HRT is necessary after breast cancer, estrogen-only therapy or estrogen therapy with a progestogen may be safer options than combined systemic therapy. [80] In women who are BRCA1 or BRCA2 mutation carriers, HRT does not appear to impact breast cancer risk. [81]
One of their recent publications was a 2019 meta-analysis of menopausal hormone therapy and breast cancer risk based on type and timing of therapy. [1] In 2012, the group concluded in a meta-analysis of 117 studies that the incidence of breast cancer was increased by each year younger at menarche and each year older at menopause. [4]
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior of cancers (measure progression or response to therapy). They can be found in bodily fluids or tissue. Markers can help with assessing prognosis, surveilling patients after surgical removal of tumors, and even predicting drug-response and monitor ...
A new study linked primary ovarian insufficiency (POI)—a condition that causes early menopause—to higher rates of breast cancer. Experts explain what to know.
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]